Bank of New York Mellon Corp - CATABASIS PHARMACEUTICALS IN ownership

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of CATABASIS PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2021$32,000
-82.5%
15,295
-75.8%
0.00%
Q1 2021$183,000
+61.9%
63,128
+19.9%
0.00%
Q4 2020$113,000
-66.7%
52,629
-4.0%
0.00%
Q3 2020$339,000
+22.8%
54,806
+27.2%
0.00%
Q2 2020$276,00043,0800.00%
Other shareholders
CATABASIS PHARMACEUTICALS IN shareholders Q3 2021
NameSharesValueWeighting ↓
Eversept Partners, LP 522,042$1,117,1700.13%
XTX MARKETS LLC 26,041$56,0000.12%
Samsara BioCapital, LLC 300,000$642,0000.06%
Ikarian Capital, LLC 650,000$1,392,0000.06%
Opaleye Management Inc. 187,750$402,0000.05%
SABBY MANAGEMENT, LLC 108,026$231,0000.04%
Anson Funds Management LP 97,601$209,0000.04%
Virtu Financial LLC 83,221$178,0000.02%
GSA CAPITAL PARTNERS LLP 47,084$101,0000.02%
WEXFORD CAPITAL LP 19,512$42,0000.01%
View complete list of CATABASIS PHARMACEUTICALS IN shareholders